Belviq is finally available in pharmacies, nearly a year after its FDA approval in June 2012.
DEA approval was required before the launch because of some of the side effects at higher doses, causing the delay in availability. Belviq is now being released as a Schedule IV drug, the second least restrictive DEA classification. This means it is considered to have a low potential for abuse compared to higher schedules and has an accepted medical use. Ambien, Provigil, and phentermine (Adipex-P) are other examples of Schedule IV drugs.
There are some reasons to be excited about Belviq: the average weight loss on Belviq over a year is 3% – 3.7%, up to about 5%. It’s also important to be aware of the potential side effects though, including slowed thinking, sleepiness, confusion, and hallucinations and euphoria at higher doses.